Bright Minds Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRUG research report →
Range $145 – $220
Price Chart
About the company
Bright Minds Biosciences Inc. , a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
- CEO
- Ian McDonald
- IPO
- 2021
- Employees
- 26
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on DRUG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $768.88M
- P/E
- -37.73
- PEG
- 0.51
- P/S
- 0.00
- P/B
- 3.49
- EV/EBITDA
- -19.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -12.56%
- ROIC
- -12.92%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-13,937,584
- Net Income
- $-12,229,348-336.5%
- EPS
- $-1.78-173.8%
- OCF Growth
- -369.8%
- FCF Growth
- -369.8%
- 52W High
- $123.75
- 52W Low
- $38.00
- 50D MA
- $72.00
- 200D MA
- $76.95
- Beta
- 0.09
- RSI (14)
- 52
- Avg Volume
- 302.27K
No earnings-call transcripts are available for DRUG yet.
- Free Float
- 62.4%
- Shares Outstanding
- 9.79M
- Float Shares
- 6.11M
of shares held by institutions
74 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 1.28M | ▲ 128.33K |
| Vanguard Group Inc | 48.58K | ▲ 3.47K |
| California State Teachers Retirement System | 380 | ▲ 70 |
| Cwm, LLC | 11 | ▲ 1 |
Held by 19 ETFs
Biggest fund positions in DRUG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | Cormorant Asset Management, LP | sell | 109,331 |
| Nov 4, 24 | Cormorant Asset Management, LP | buy | 184,331 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 3,107 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 7,150 |
| Oct 16, 24 | Cormorant Asset Management, LP | buy | 39,743 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 4,609 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 19,169 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,700 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 2,600 |
| Oct 15, 24 | Cormorant Asset Management, LP | buy | 8,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRUG coverage
Recent articles, reports, and earnings notes.
No research on DRUG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRUG report →Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
zacks.com · Aug 10
Vistagen Appoints Douglas J. Williamson to its Board of Directors
globenewswire.com · Jul 31
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
zacks.com · Jul 23
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
zacks.com · Jul 22
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
globenewswire.com · May 26
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
fool.com · May 21
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages
defenseworld.net · Mar 28
Bright Minds Biosciences to Present at Upcoming Conferences
globenewswire.com · Feb 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.